Director/PDMR Notification

RNS Number : 4295D
Advanced Oncotherapy PLC
02 March 2022
 

2 March 2022

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Director/PDMR Notification

 

Advanced Oncotherapy (AIM: AVO), LIGHT, the next-generation proton therapy system for cancer treatment, announces that Enrico Vanni, Non-Executive Director, has purchased 100,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares"), at a price of 26.5 pence per share. Following this purchase, Mr Vanni now has a total interest in 3,496,361 Ordinary Shares, equivalent to 0.77% of the Company's issued share capital.

 

The notification below, which has been made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited  (Nomad and Joint Broker)


Nick Athanas / Liz Kirchner (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

Tel: +44 (0) 20 3328 5656



SI Capital Ltd  (Joint Broker)


Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

 

1

Details of the person discharging managerial responsibilities

a)

Name

Enrico Vanni

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

b)

Nature of the transaction

Purchase of shares

c)

Price(s) and volume(s)

Price: 26.5p

Volume: 100,000 shares

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

2 March 2022

 

f)

Place of the transaction

London Stock Exchange, (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZGGFVZVGZZM
UK 100

Latest directors dealings